The Food and Drug Administration is requiring Eli Lilly (LLY) to hire consultants to test batches and vet quality-testing data at a manufacturing plant where its Covid-19 antibody treatment is being made, a mandate that comes after the agency found quality control problems during two separate inspections over the past year.
The stipulations were included in a Nov. 10 letter the agency sent to the drug maker authorizing the use of bamlanivimab for treating adults and children with mild-to-moderate cases of Covid-19. If reviews by independent consultants find any batch or data discrepancies with “significant potential to affect critical quality attributes,” the drug cannot be released until the problems are resolved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
